207 related articles for article (PubMed ID: 22479338)
1. Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells.
Chapman R; Shephard E; Stutz H; Douglass N; Sambandamurthy V; Garcia I; Ryffel B; Jacobs W; Williamson AL
PLoS One; 2012; 7(3):e32769. PubMed ID: 22479338
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice.
Jongwe TI; Chapman R; Douglass N; Chetty S; Chege G; Williamson AL
PLoS One; 2016; 11(7):e0159141. PubMed ID: 27427967
[TBL] [Abstract][Full Text] [Related]
3. Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.
Chege GK; Burgers WA; Stutz H; Meyers AE; Chapman R; Kiravu A; Bunjun R; Shephard EG; Jacobs WR; Rybicki EP; Williamson AL
J Virol; 2013 May; 87(9):5151-60. PubMed ID: 23449790
[TBL] [Abstract][Full Text] [Related]
4. Priming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a robust T cell response in mice.
Chapman R; Stutz H; Jacobs W; Shephard E; Williamson AL
PLoS One; 2013; 8(8):e71601. PubMed ID: 23977084
[TBL] [Abstract][Full Text] [Related]
5. Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.
Promkhatkaew D; Matsuo K; Pinyosukhee N; Thongdeejaroen W; Leang-Aramgul P; Sawanpanyalert P; Warachit P
Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):273-81. PubMed ID: 19323012
[TBL] [Abstract][Full Text] [Related]
6. Preclinical development of BCG.HIVA
Mahant A; Saubi N; Eto Y; Guitart N; Gatell JM; Hanke T; Joseph J
Hum Vaccin Immunother; 2017 Aug; 13(8):1798-1810. PubMed ID: 28426273
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.
Saubi N; Mbewe-Mvula A; Gea-Mallorqui E; Rosario M; Gatell JM; Hanke T; Joseph J
PLoS One; 2012; 7(8):e42559. PubMed ID: 22927933
[TBL] [Abstract][Full Text] [Related]
8. Prime-boost immunization of codon optimized HIV-1 CRF01_AE Gag in BCG with recombinant vaccinia virus elicits MHC class I and II immune responses in mice.
Promkhatkaew D; Pinyosukhee N; Thongdeejaroen W; Teeka J; Wutthinantiwong P; Leangaramgul P; Sawanpanyalert P; Warachit P
Immunol Invest; 2009; 38(8):762-79. PubMed ID: 19860587
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of the vaccinia virus LC16m8Δ vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol.
Sato H; Jing C; Isshiki M; Matsuo K; Kidokoro M; Takamura S; Zhang X; Ohashi T; Shida H
Vaccine; 2013 Aug; 31(35):3549-57. PubMed ID: 23731631
[TBL] [Abstract][Full Text] [Related]
10. Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors.
Hopkins R; Bridgeman A; Bourne C; Mbewe-Mvula A; Sadoff JC; Both GW; Joseph J; Fulkerson J; Hanke T
Eur J Immunol; 2011 Dec; 41(12):3542-52. PubMed ID: 21932450
[TBL] [Abstract][Full Text] [Related]
11. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
[TBL] [Abstract][Full Text] [Related]
12. Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.
Kim BJ; Kim BR; Kook YH; Kim BJ
Front Immunol; 2018; 9():643. PubMed ID: 29636755
[TBL] [Abstract][Full Text] [Related]
13. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandström E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
J Virol; 2017 Sep; 91(18):. PubMed ID: 28701395
[TBL] [Abstract][Full Text] [Related]
14. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.
Goonetilleke N; Moore S; Dally L; Winstone N; Cebere I; Mahmoud A; Pinheiro S; Gillespie G; Brown D; Loach V; Roberts J; Guimaraes-Walker A; Hayes P; Loughran K; Smith C; De Bont J; Verlinde C; Vooijs D; Schmidt C; Boaz M; Gilmour J; Fast P; Dorrell L; Hanke T; McMichael AJ
J Virol; 2006 May; 80(10):4717-28. PubMed ID: 16641265
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.
Tchilian EZ; Desel C; Forbes EK; Bandermann S; Sander CR; Hill AV; McShane H; Kaufmann SH
Infect Immun; 2009 Feb; 77(2):622-31. PubMed ID: 19064635
[TBL] [Abstract][Full Text] [Related]
16. Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B'.
Chen Z; Huang Y; Zhao X; Ba L; Zhang W; Ho DD
J Acquir Immune Defic Syndr; 2008 Apr; 47(4):412-21. PubMed ID: 18209682
[TBL] [Abstract][Full Text] [Related]
17. A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons.
Chege GK; Thomas R; Shephard EG; Meyers A; Bourn W; Williamson C; Maclean J; Gray CM; Rybicki EP; Williamson AL
Vaccine; 2009 Jul; 27(35):4857-66. PubMed ID: 19520196
[TBL] [Abstract][Full Text] [Related]
18. CD8 T Cells Show Protection against Highly Pathogenic Simian Immunodeficiency Virus (SIV) after Vaccination with SIV Gene-Expressing BCG Prime and Vaccinia Virus/Sendai Virus Vector Boosts.
Kato S; Shida H; Okamura T; Zhang X; Miura T; Mukai T; Inoue M; Shu T; Naruse TK; Kimura A; Yasutomi Y; Matsuo K
J Virol; 2021 Jan; 95(4):. PubMed ID: 33087465
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
Rosario M; Fulkerson J; Soneji S; Parker J; Im EJ; Borthwick N; Bridgeman A; Bourne C; Joseph J; Sadoff JC; Hanke T
J Virol; 2010 Aug; 84(15):7815-21. PubMed ID: 20484495
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses.
Cayabyab MJ; Korioth-Schmitz B; Sun Y; Carville A; Balachandran H; Miura A; Carlson KR; Buzby AP; Haynes BF; Jacobs WR; Letvin NL
J Virol; 2009 Jun; 83(11):5505-13. PubMed ID: 19297477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
